Skip to main content
. 2017 Mar 10;15:54. doi: 10.1186/s12916-017-0807-7

Table 2.

Type of thrombotic event and antithrombotic therapy at the time of event

Type of TE Total
n (%)
On VKA
n (%)
On LMWH
n (%)
On LDA
n (%)
No AC
n (%)
All TE 32 (100.0%) 14 (45.2%) 4 (12.9%) 7 (22.6%) 8 (25.8%)
Venous TE 16 (50.0%) 8 (53.3%) 3 (20.0%) 3 (20.0%) 3 (20.0%)
Lower extremity DVT 6 (18.8%) 4 (66.7%) 0 (0.0%) 0 (0.0%) 2 (33.3%)
Isolated PE 6 (18.8%) 2 (40.0%) 1 (20.0%) 2 (40.0%) 1 (20.0%)
Lower extremity DVT + PE 1 (3.1%) 1 (100.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Upper extremity DVT 1 (3.1%) 0 (0.0%) 1 (100.0%) 1 (100.0%) 0 (0.0%)
Renal vein thrombosis 1 (3.1%) 0 (0.0%) 1 (100.0%) 0 (0.0%) 0 (0.0%)
Ocular vein thrombosis 1 (3.1%) 1 (100.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Arterial TE 16 (50.0%) 6 (37.5%) 1 (6.3%) 4 (25.0%) 5 (31.3%)
Stroke 8 (25.0%) 3 (37.5%) 0 (0.0%) 1 (12.5%) 3 (37.5%)
TIA 1 (3.1%) 1 (100.0%) 0 (0.0%) 1 (100.0%) 0 (0.0%)
Myocardial infarction 5 (15.6%) 1 (20.0%) 1 (20.0%) 1 (20.0%) 2 (40.0%)
Peripheral artery TE 2 (6.3%) 1 (50.0%) 0 (0.0%) 1 (50.0%) 0 (0.0%)

TE thrombotic events, DVT deep vein thrombosis, PE pulmonary embolism, VKA vitamin K antagonist, LMWH low molecular weight heparin, LDA low dose aspirin, AC anticoagulation